Diallyl sulfide: Potential use in novel therapeutic interventions in alcohol, drugs, and disease mediated cellular toxicity by targeting cytochrome P450 2E1

Current Drug Metabolism

Volumn 16, Issue 6, 2015, Pages 486-503

  Rao, P S S ^a   Midde, Narasimha M ^a   Miller, Duane D ^a   Chauhan, Subhash ^a   Kumar, Anil ^b   Kumar, Santosh ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Alcohol; Cancer; CYP2E1; Diallyl sulfide

Indexed keywords

ALCOHOL; ALLYL SULFIDE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CYTOCHROME P450 2E1; CYTOCHROME P450 2E1 INHIBITOR; DRUG METABOLIZING ENZYME; NEUROPROTECTIVE AGENT; ORGANOSULFUR DERIVATIVE; XENOBIOTIC AGENT; ALLYL COMPOUND; PROTECTIVE AGENT; SULFIDE;

ACTIVE TRANSPORT; ALCOHOL OXIDATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; COLON CANCER; CYTOTOXICITY; DIABETES MELLITUS; DRUG METABOLISM; DRUG TRANSPORT; DRUG USE; EFFUSION; ENZYME ACTIVITY; GARLIC; GENE CONTROL; GENE EXPRESSION; GENE STRUCTURE; GENETIC CODE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID DIET; LUNG CARCINOGENESIS; MOLECULAR MODEL; NEUROPROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PARKINSON DISEASE; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; METABOLISM;

ALLYL COMPOUNDS; ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP2E1; CYTOPROTECTION; ETHANOL; HUMANS; PROTECTIVE AGENTS; SULFIDES; XENOBIOTICS;

EID: 84945399554     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666150812123554     Document Type: Article

References (180)

1. Block, E. The chemistry of garlic and onions. Sci. Am., 1985, 252 (3), 114-9.
2. Thomson, M.; Ali, M. Garlic [Allium sativum]: A Review of its Potential Use as an Anti-Cancer Agent. Curr. Cancer Drug Targets, 2003, 3 (1), 67-81.
3. Amagase, H.; Petesch, B. L.; Matsuura, H.; Kasuga, S.; Itakura, Y. Intake of garlic and its bioactive components. J. Nutr., 2001, 131 (3s), 955S-62S.
4. Omar, S. H.; Al-Wabel, N. A. Organosulfur compounds and possible mechanism of garlic in cancer. Saudi. Pharm. J., 2010, 18 (1), 51-8.
5. Iciek, M.; Kwiecien, I.; Wlodek, L. Biological Properties of Garlic and Garlic-Derived Organosulfur Compounds. Environ. Mol. Mutag., 2009, 50 (3), 247-265.
6. Egenschwind, C.; Eckard, R.; Kemper, F. H. Metabolism of Garlic Constituents in the Isolated Perfused-Rat-Liver. Planta Med., 1992, 58 (4), 301-305.
7. Freeman, F.; Kodera, Y. Garlic Chemistry - Stability of S-(2- Propenyl) 2-Propene-1-Sulfinothioate (Allicin) in Blood, Solvents, and Simulated Physiological Fluids. J. Agric. Food Chem., 1995, 43 (9), 2332-2338.
8. Rai, S. K.; Sharma, M.; Tiwari, M. Inhibitory effect of novel diallyldisulfide analogs on HMG-CoA reductase expression in hypercholesterolemic rats: CREB as a potential upstream target. Life Sci., 2009, 85 (5-6), 211-9.
9. Yi, L.; Su, Q. Molecular mechanisms for the anti-cancer effects of diallyl disulfide. Food Chem. Toxicol., 2013, 57, 362-70.
10. Wang, H. C.; Pao, J.; Lin, S. Y.; Sheen, L. Y. Molecular mechanisms of garlic-derived allyl sulfides in the inhibition of skin cancer progression. Ann. N. Y. Acad. Sci., 2012, 1271, 44-52.
11. Karmakar, S.; Banik, N. L.; Patel, S. J.; Ray, S. K. Garlic compounds induced calpain and intrinsic caspase cascade for apoptosis in human malignant neuroblastoma SH-SY5Y cells. Apoptosis, 2007, 12 (4), 671-84.
12. Cao, H. X.; Zhu, K. X.; Fan, J. G.; Qiao, L. Garlic-derived allyl sulfides in cancer therapy. Anticancer Agents Med. Chem., 2014, 14 (6), 793-9.
13. Wargovich, M. J.; Goldberg, M. T. Diallyl sulfide. A naturally occurring thioether that inhibits carcinogen-induced nuclear damage to colon epithelial cells in vivo. Mutat. Res., 1985, 143 (3), 127-9.
14. Hayes, M. A.; Rushmore, T. H.; Goldberg, M. T. Inhibition of hepatocarcinogenic responses to 1,2-dimethylhydrazine by diallyl sulfide, a component of garlic oil. Carcinogenesis, 1987, 8 (8), 1155-7.
15. Hong, J. Y.; Wang, Z. Y.; Smith, T. J.; Zhou, S.; Shi, S.; Pan, J.; Yang, C. S. Inhibitory effects of diallyl sulfide on the metabolism and tumorigenicity of the tobacco-specific carcinogen 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in A/J mouse lung. Carcinogenesis, 1992, 13 (5), 901-904.
16. Haber-Mignard, D.; Suschetet, M.; Berges, R.; Astorg, P.; Siess, M. H. Inhibition of aflatoxin B1- and N-nitrosodiethylamineinduced liver preneoplastic foci in rats fed naturally occurring allyl sulfides. Nutr. Cancer, 1996, 25 (1), 61-70.
17. Wu, P. P.; Chung, H. W.; Liu, K. C.; Wu, R. S. C.; Yang, J. S.; Tang, N. Y.; Lo, C.; Hsia, T. C.; Yu, C. C.; Chueh, F. S.; Lin, S. S.; Chung, J. G. Diallyl sulfide induces cell cycle arrest and apoptosis in HeLa human cervical cancer cells through the p53, caspase- and mitochondria-dependent pathways. Int. J. Oncol., 2011, 38 (6), 1605-1613.
18. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 1997, 88 (3), 323-331.
19. Kalra, N.; Arora, A.; Shukla, Y. Involvement of multiple signaling pathways in diallyl sulfide mediated apoptosis in mouse skin tumors. Asian Pac. J. Cancer Prev., 2006, 7 (4), 556-62.
20. George, J.; Singh, M.; Srivastava, A. K.; Bhui, K.; Shukla, Y. Synergistic growth inhibition of mouse skin tumors by pomegranate fruit extract and diallyl sulfide: evidence for inhibition of activated MAPKs/NF-kappaB and reduced cell proliferation. Food Chem. Toxicol., 2011, 49 (7), 1511-20.
21. Shin, H. A.; Cha, Y. Y.; Park, M. S.; Kim, J. M.; Lim, Y. C. Diallyl sulfide induces growth inhibition and apoptosis of anaplastic thyroid cancer cells by mitochondrial signaling pathway. Oral Oncol., 2010, 46 (4), e15-8.
22. Chiu, T. H.; Lan, K. Y.; Yang, M. D.; Lin, J. J.; Hsia, T. C.; Wu, C. T.; Yang, J. S.; Chueh, F. S.; Chung, J. G. Diallyl Sulfide Promotes Cell-Cycle Arrest Through the p53 Expression and Triggers Induction of Apoptosis Via Caspase- and Mitochondria-Dependent Signaling Pathways in Human Cervical Cancer Ca Ski Cells. Nutr. Cancer, 2013, 65 (3), 505-514.
23. Oyadomari, S.; Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ., 2004, 11 (4), 381-389.
24. Storr, S. J.; Carragher, N. O.; Frame, M. C.; Parr, T.; Martin, S. G. The calpain system and cancer. Nat. Rev. Cancer, 2011, 11 (5), 364-74.
25. Yu, F. S.; Wu, C. C.; Chen, C. T.; Huang, S. P.; Yang, J. S.; Hsu, Y. M.; Wu, P. P.; Ip, S. W.; Lin, J. P.; Lin, J. G.; Chung, J. G. Diallyl sulfide inhibits murine WEHI-3 leukemia cells in BALB/c mice in vitro and in vivo. Hum. Exp. Toxicol., 2009, 28 (12), 785-790.
26. Lai, K. C.; Hsu, S. C.; Kuo, C. L.; Yang, J. S.; Ma, C. Y.; Lu, H. F.; Tang, N. Y.; Hsia, T. C.; Ho, H. C.; Chung, J. G. Diallyl sulfide, diallyl disulfide, and diallyl trisulfide inhibit migration and invasion in human colon cancer colo 205 cells through the inhibition of matrix metalloproteinase-2,-7, and-9 expressions. Environ. Toxicol., 2013, 28 (9), 479-488.
27. Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J., 2011, 278 (1), 16-27.
28. Kang, J. S.; Kim, T. M.; Shim, T. J.; Salim, E. I.; Han, B. S.; Kim, D. J. Modifying effect of diallyl sulfide on colon carcinogenesis in C57BL/6J-ApcMin/(+) mice. Asian Pac. J. Cancer Prev., 2012, 13 (4), 1115-8.
29. Fleischauer, A. T.; Poole, C.; Arab, L. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am. J. Clin. Nutr., 2000, 72 (4), 1047-1052.
30. Cherng, J. M.; Tsai, K. D.; Perng, D. S.; Wang, J. S.; Wei, C. C.; Lin, J. C. Diallyl sulfide protects against ultraviolet B-induced skin cancers in SKH-1 hairless mouse: analysis of early molecular events in carcinogenesis. Photodermatol. Photoimmunol. Photomed., 2011, 27 (3), 138-146.
31. Vaclavikova, R.; Hubackova, M.; Stribrna-Sarmanova, J.; Kodet, R.; Mrhalova, M.; Novotny, J.; Gut, I.; Soucek, P. RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res., 2007, 27 (6C), 4443-50.
32. Danko, I. M.; Chaschin, N. A. Association of CYP2E1 gene polymorphism with predisposition to cancer development. Exp. Oncol., 2005, 27 (4), 248-56.
33. Xu, L.; Yang, M.; Zhao, T.; Jin, H.; Xu, Z.; Li, M.; Chen, H. The polymorphism of CYP2E1 Rsa I/Pst I gene and susceptibility to respiratory system cancer: a systematic review and meta-analysis of 34 studies. Medicine (Baltimore), 2014, 93 (27), e178.
34. Kiss, I.; Orsos, Z.; Gombos, K.; Bogner, B.; Csejtei, A.; Tibold, A.; Varga, Z.; Pazsit, E.; Magda, I.; Zolyomi, A.; Ember, I. Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. Anticancer Res., 2007, 27 (4C), 2931-7.
35. Linhart, K.; Bartsch, H.; Seitz, H. K. The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts. Redox Biol., 2014, 3, 56-62.
36. Ibrahim, S. S.; Nassar, N. N. Diallyl sulfide protects against Nnitrosodiethylamine- induced liver tumorigenesis: role of aldose reductase. World J. Gastroenterol., 2008, 14 (40), 6145-53.
37. Kalayarasan, S.; Prabhu, P. N.; Sriram, N.; Manikandan, R.; Arumugam, M.; Sudhandiran, G. Diallyl sulfide enhances antioxidants and inhibits inflammation through the activation of Nrf2 against gentamicin-induced nephrotoxicity in Wistar rats. Eur. J. Pharmacol., 2009, 606 (1-3), 162-171.
38. Ho, C. Y.; Cheng, Y. T.; Chau, C. F.; Yen, G. C. Effect of diallyl sulfide on in vitro and in vivo Nrf2-mediated pulmonic antioxidant enzyme expression via activation ERK/p38 signaling pathway. J. Agric. Food Chem., 2012, 60 (1), 100-7.
39. Ho, C. Y.; Weng, C. J.; Jhang, J. J.; Cheng, Y. T.; Huang, S. M.; Yen, G. C. Diallyl sulfide as a potential dietary agent to reduce TNF-alpha- and histamine-induced proinflammatory responses in A7r5 cells. Mol. Nutr. Food Res., 2014, 58 (5), 1069-1078.
40. Kalayarasan, S.; Sriram, N.; Sudhandiran, G. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. Life Sci., 2008, 82 (23-24), 1142-53.
41. Lee, H. S.; Lee, C. H.; Tsai, H. C.; Salter, D. M. Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-1beta. Osteoarthritis Cartilage, 2009, 17 (1), 91-9.
42. Shaik, I. H.; George, J. M.; Thekkumkara, T. J.; Mehvar, R. Protective effects of diallyl sulfide, a garlic constituent, on the warm hepatic ischemia-reperfusion injury in a rat model. Pharm. Res., 2008, 25 (10), 2231-42.
43. Green, M.; Newell, O.; Aboyade-Cole, A.; Darling-Reed, S.; Thomas, R. D. Diallyl sulfide induces the expression of nucleotide excision repair enzymes in the breast of female ACI rats. Toxicol. Lett., 2007, 168 (1), 40-44.
44. Albertson, T. M.; Ogawa, M.; Bugni, J. M.; Hays, L. E.; Chen, Y.; Wang, Y. P.; Treuting, P. M.; Heddle, J. A.; Goldsby, R. E.; Preston, B. D. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc. Natl. Acad. Sci. U. S. A., 2009, 106 (40), 17101-17104.
45. Smith, M. L.; Ford, J. M.; Hollander, M. C.; Bortnick, R. A.; Amundson, S. A.; Seo, Y. R.; Deng, C. X.; Hanawalt, P. C.; Fornace, A. J. p53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol. Cell. Biol., 2000, 20 (10), 3705-3714.
46. Stolimenov, I.; Helleday, T. PCNA on the crossroad of cancer. Biochem. Soc. Trans., 2009, 37, 605-613.
47. Aboyade-Cole, A.; Darling-Reed, S.; Oriaku, E.; McCaskill, M.; Thomas, R. Diallyl sulfide inhibits PhIP-induced cell death via the inhibition of DNA strand breaks in normal human breast epithelial cells. Oncol. Rep., 2008, 20 (2), 319-23.
48. McCaskill, M. L.; Rogan, E.; Thomas, R. D. Diallyl sulfide inhibits diethylstilbestrol induced DNA damage in human breast epithelial cells (MCF-10A). Steroids, 2014, 92, 96-100.
49. Katoch, O.; Khan, G. A.; Dwarakanath, B. S.; Agrawala, P. K. Mitigation of hematopoietic radiation injury by diallyl sulphide. J. Environ. Pathol. Toxicol. Oncol., 2012, 31 (4), 357-65.
50. Lin, X. M.; Yu, S. S.; Chen, Y. L.; Wu, J. X.; Zhao, J.; Zhao, Y. Neuroprotective effects of diallyl sulfide against transient focal cerebral ischemia via anti-apoptosis in rats. Neurol. Res., 2012, 34 (1), 32-37.
51. Kim, N. H.; Lee, S.; Kang, M. J.; Jeong, H. G.; Kang, W.; Jeong, T. C. Protective Effects of Diallyl Sulfide against Thioacetamide- Induced Toxicity: A Possible Role of Cytochrome P450 2E1. Biomol. Ther. (Seoul), 2014, 22 (2), 149-154.
52. Yanagiba, Y.; Suzuki, T.; Suda, M.; Hojo, R.; Gonzalez, F. J.; Nakajima, T.; Wang, R. S. Cytochrome P450 2E1 is responsible for the initiation of 1,2-dichloropropane-induced liver damage. Toxicol. Ind. Health, 2015.
53. Jeong, H. G.; Lee, Y. W. Protective effects of diallyl sulfide on Nnitrosodimethylamine- induced immunosuppression in mice. Cancer Lett., 1998, 134 (1), 73-9.
54. Kathawala, R. J.; Gupta, P.; Ashby, C. R. Jr.; Chen, Z. S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist. Updat., 2015, 18C, 1-17.
55. Lai, K. C.; Kuo, C. L.; Ho, H. C.; Yang, J. S.; Ma, C. Y.; Lu, H. F.; Huang, H. Y.; Chueh, F. S.; Yu, C. C.; Chung, J. G. Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo. Phytomedicine, 2012, 19 (7), 625-630.
56. Cherrington, N. J.; Slitt, A. L.; Maher, J. M.; Zhang, X. X.; Zhang, J.; Huang, W. D.; Wan, Y. J. Y.; Moore, D. D.; Klaassen, C. D. Induction of multidrug resistance protein 3 (MRP3) in vivo is independent of constitutive androstane receptor. Drug Metab. Dispos., 2003, 31 (11), 1315-1319.
57. Slitt, A. L.; Cherrington, N. J.; Maher, J. M.; Klaassen, C. D. Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab. Dispos., 2003, 31 (9), 1176-1186.
58. Maher, J. M.; Cheng, X. G.; Slitt, A. L.; Dieter, M. Z.; Klaassen, C. D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos., 2005, 33 (7), 956-962.
59. Arora, A.; Seth, K.; Shukla, Y. Reversal of P-glycoproteinmediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis, 2004, 25 (6), 941-949.
60. Iyanagi, T. Molecular mechanism of phase I and phase II drugmetabolizing enzymes: Implications for detoxification. Int. Rev. Cytol., 2007, 260, 35-112.
61. Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase Ii Drug Metabolizing Enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub., 2010, 154 (2), 103-116.
62. Lubet, R. A.; Yao, R.; Grubbs, C. J.; You, M.; Wang, Y. Induced expression of drug metabolizing enzymes by preventive agents: role of the antioxidant response element. Chem. Biol. Interact., 2009, 182 (1), 22-8.
63. Guyonnet, D.; Belloir, C.; Suschetet, M.; Siess, M. H.; Le Bon, A. M. Mechanisms of protection against aflatoxin B(1) genotoxicity in rats treated by organosulfur compounds from garlic. Carcinogenesis, 2002, 23 (8), 1335-41.
64. Fisher, C. D.; Augustine, L. M.; Maher, J. M.; Nelson, D. M.; Slitt, A. L.; Klaassen, C. D.; Lehman-McKeeman, L. D.; Cherrington, N. J. Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab. Dispos., 2007, 35 (6), 995-1000.
65. Sueyoshi, T.; Green, W. D.; Vinal, K.; Woodrum, T. S.; Moore, R.; Negishi, M. Garlic Extract Diallyl Sulfide (DAS) Activates Nuclear Receptor CAR to Induce the Sult1e1 Gene in Mouse Liver. Plos One, 2011, 6 (6).
66. Guyonnet, D.; Siess, M. H.; Le Bon, A. M.; Suschetet, M. Modulation of phase II enzymes by organosulfur compounds from allium vegetables in rat tissues. Toxicol. Appl. Pharmacol., 1999, 154 (1), 50-58.
67. Trafalis, D. T.; Panteli, E. S.; Grivas, A.; Tsigris, C.; Karamanakos, P. N. CYP2E1 and risk of chemically mediated cancers. Expert Opin. Drug Metab. Toxicol., 2010, 6 (3), 307-319.
68. Wu, D.; Cederbaum, A. I. Oxidative stress mediated toxicity exerted by ethanol-inducible CYP2E1. Toxicol. Appl. Pharmacol., 2005, 207 (2 Suppl), 70-6.
69. Jin, L.; Baillie, T. A. Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem. Res. Toxicol., 1997, 10 (3), 318-327.
70. Davenport, D. M.; Wargovich, M. J. Modulation of cytochrome P450 enzymes by organosulfur compounds from garlic. Food Chem. Toxicol., 2005, 43 (12), 1753-1762.
71. Lieber, C. S. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev., 1997, 77 (2), 517-544.
72. Cederbaum, A. I. Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant defense in liver cells. J. Gastroenterol. Hepatol., 2006, 21 Suppl 3, S22-25.
73. Lu, Y.; Cederbaum, A. I. CYP2E1 and oxidative liver injury by alcohol. Free Radic. Biol. Med., 2008, 44 (5), 723-738.
74. Kumar, S.; Jin, M.; Ande, A.; Sinha, N.; Silverstein, P. S.; Kumar, A. Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin. Drug Metab. Toxicol., 2012, 8 (11), 1363-1375.
75. Miller, A. M.; Horiguchi, N.; Jeong, W.-I.; Radaeva, S.; Gao, B. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol. Clin. Exp. Res., 2011, 35 (5), 787-793.
76. Zeng, T.; Zhang, C.-L.; Song, F.-Y.; Zhao, X.-L.; Xie, K.-Q. CMZ reversed chronic ethanol-induced disturbance of PPAR-α possibly by suppressing oxidative stress and PGC-1α acetylation, and activating the MAPK and GSK3β pathway. PLoS One, 2014, 9 (6).
77. Ceni, E.; Mello, T.; Galli, A. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J. Gastroenterol., 2014, 20 (47), 17756-17772.
78. Donohue, T. M. Jr.; Thomes, P. G. Ethanol-induced oxidant stress modulates hepatic autophagy and proteasome activity. Redox Biol., 2014, 3, 29-39.
79. Wang, X.; Wu, D.; Yang, L.; Gan, L.; Cederbaum, A. I. Cytochrome P450 2E1 potentiates ethanol induction of hypoxia and HIF-1α in vivo. Free Radic. Biol. Med., 2013, 63, 175-186.
80. Yun, J.-W.; Son, M.-J.; Abdelmegeed, M. A.; Banerjee, A.; Morgan, T. R.; Yoo, S.-H.; Song, B.-J. Binge alcohol promotes hypoxic liver injury through a CYP2E1-HIF-1α-dependent apoptosis pathway in mice and humans. Free Radic. Biol. Med., 2014, 77, 183-194.
81. Lieber, C. S.; DeCarli, L. M. The role of the hepatic microsomal ethanol oxidizing system (MEOS) for ethanol metabolism in vivo. J. Pharmacol. Exp. Ther., 1972, 181 (2), 279-287.
82. Matsumoto, H.; Matsubayashi, K.; Fukui, Y. Evidence that cytochrome P-4502E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4-methyl pyrazole on ethanol elimination in the perfused rat liver. Alcohol. Clin. Exp. Res., 1996, 20 (1 Suppl), 12A-16A.
83. Morimoto, M.; Hagbjörk, A. L.; Wan, Y. J.; Fu, P. C.; Clot, P.; Albano, E.; Ingelman-Sundberg, M.; French, S. W. Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology, 1995, 21 (6), 1610-1617.
84. Kishimoto, R.; Ueda, M.; Yoshinaga, H.; Goda, K.; Park, S. S. Combined effects of ethanol and garlic on hepatic ethanol metabolism in mice. J. Nutr. Sci. Vitaminol., 1999, 45 (3), 275-286.
85. Morimoto, M.; Reitz, R. C.; Morin, R. J.; Nguyen, K.; Ingelman- Sundberg, M.; French, S. W. CYP-2E1 inhibitors partially ameliorate the changes in hepatic fatty acid composition induced in rats by chronic administration of ethanol and a high fat diet. J. Nutr., 1995, 125 (12), 2953-2964.
86. Wu, D.; Cederbaum, A. I. Cyclosporine A protects against arachidonic acid toxicity in rat hepatocytes: role of CYP2E1 and mitochondria. Hepatology, 2002, 35 (6), 1420-1430.
87. Liu, L.-G.; Yan, H.; Yao, P.; Zhang, W.; Zou, L.-J.; Song, F.-F.; Li, K.; Sun, X.-F. CYP2E1-dependent hepatotoxicity and oxidative damage after ethanol administration in human primary hepatocytes. World J. Gastroenterol., 2005, 11 (29), 4530-4535.
88. Phillips, M.; Curtis, H.; Portmann, B.; Donaldson, N.; Bomford, A.; O'Grady, J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-a randomised clinical trial. J. Hepatol., 2006, 44 (4), 784-790.
89. Stewart, S.; Prince, M.; Bassendine, M.; Hudson, M.; James, O.; Jones, D.; Record, C.; Day, C. P. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J. Hepatol., 2007, 47 (2), 277-283.
90. Kono, H.; Rusyn, I.; Bradford, B. U.; Connor, H. D.; Mason, R. P.; Thurman, R. G. Allopurinol prevents early alcohol-induced liver injury in rats. J. Pharmacol. Exp. Ther., 2000, 293 (1), 296-303.
91. Kono, H.; Arteel, G. E.; Rusyn, I.; Sies, H.; Thurman, R. G. Ebselen prevents early alcohol-induced liver injury in rats. Free Radic. Biol. Med., 2001, 30 (4), 403-411.
92. Kono, H.; Rusyn, I.; Uesugi, T.; Yamashina, S.; Connor, H. D.; Dikalova, A.; Mason, R. P.; Thurman, R. G. Diphenyleneiodonium sulfate, an NADPH oxidase inhibitor, prevents early alcoholinduced liver injury in the rat. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 280 (5), G1005-1012.
93. Mato, J. M.; Cámara, J.; Fernández de Paz, J.; Caballería, L.; Coll, S.; Caballero, A.; García-Buey, L.; Beltrán, J.; Benita, V.; Caballería, J.; Solà, R.; Moreno-Otero, R.; Barrao, F.; Martín-Duce, A.; Correa, J. A.; Parés, A.; Barrao, E.; García-Magaz, I.; Puerta, J. L.; Moreno, J.; Boissard, G.; Ortiz, P.; Rodés, J. Sadenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo- controlled, double-blind, multicenter clinical trial. J. Hepatol., 1999, 30 (6), 1081-1089.
94. Addolorato, G.; Ancona, C.; Capristo, E.; Gasbarrini, G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int. J. Immunopathol. Pharmacol., 2003, 16 (3), 207-214.
95. Ki, S. H.; Choi, J. H.; Kim, C. W.; Kim, S. G. Combined metadoxine and garlic oil treatment efficaciously abrogates alcoholic steatosis and CYP2E1 induction in rat liver with restoration of AMPK activity. Chem.-Biol. Interact., 2007, 169 (2), 80-90.
96. Swaminathan, K.; Clemens, D. L.; Dey, A. Inhibition of CYP2E1 leads to decreased malondialdehyde-acetaldehyde adduct formation in VL-17A cells under chronic alcohol exposure. Life Sci., 2013, 92 (6-7), 325-336.
97. Ronis, M. J.; Korourian, S.; Blackburn, M. L.; Badeaux, J.; Badger, T. M. The role of ethanol metabolism in development of alcoholic steatohepatitis in the rat. Alcohol, 2010, 44 (2), 157-169.
98. Lu, Y.; Wu, D.; Wang, X.; Ward, S. C.; Cederbaum, A. I. Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. Free Radic. Biol. Med., 2010, 49 (9), 1406-16.
99. Zeng, T.; Zhang, C.-L.; Song, F.-Y.; Zhao, X.-L.; Xie, K.-Q. Garlic oil alleviated ethanol-induced fat accumulation via modulation of SREBP-1, PPAR-α, and CYP2E1. Food Chem. Toxicol., 2012, 50 (3-4), 485-491.
100. Bansal, S.; Srinivasan, S.; Anandasadagopan, S.; Chowdhury, A. R.; Selvaraj, V.; Kalyanaraman, B.; Joseph, J.; Avadhani, N. G. Additive effects of mitochondrion-targeted cytochrome CYP2E1 and alcohol toxicity on cytochrome c oxidase function and stability of respirosome complexes. J. Biol. Chem., 2012, 287 (19), 15284-15297.
101. Raza, H.; John, A. 4-hydroxynonenal induces mitochondrial oxidative stress, apoptosis and expression of glutathione S-transferase A4-4 and cytochrome P450 2E1 in PC12 cells. Toxicol. Appl. Pharmacol., 2006, 216 (2), 309-18.
102. Bardag-Gorce, F.; French, B. A.; Nan, L.; Song, H.; Nguyen, S. K.; Yong, H.; Dede, J.; French, S. W. CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp. Mol. Pathol., 2006, 81 (3), 191-201.
103. Novak, R. F.; Woodcroft, K. J. The alcohol-inducible form of cytochrome P450 (CYP 2E1): role in toxicology and regulation of expression. Arch. Pharm. Res., 2000, 23 (4), 267-282.
104. Jin, M.; Ande, A.; Kumar, A.; Kumar, S. Regulation of cytochrome P450 2e1 expression by ethanol: role of oxidative stress-mediated pkc/jnk/sp1 pathway. Cell Death Dis., 2013, 4.
105. Wickramasinghe, S. N. Neuroglial and neuroblastoma cell lines are capable of metabolizing ethanol via an alcohol-dehydrogenaseindependent pathway. Alcohol. Clin. Exp. Res., 1987, 11 (3), 234-7.
106. Wickramasinghe, S. N. Observations on the biochemical basis of ethanol metabolism by human macrophages. Alcohol Alcohol., 1986, 21 (1), 57-63.
107. Zimatkin, S. M.; Pronko, S. P.; Vasiliou, V.; Gonzalez, F. J.; Deitrich, R. A. Enzymatic mechanisms of ethanol oxidation in the brain. Alcohol. Clin. Exp. Res., 2006, 30 (9), 1500-5.
108. Silverstein, P. S.; Kumar, S.; Kumar, A. HIV-1, HCV and alcohol in the CNS: potential interactions and effects on neuroinflammation. Curr. HIV Res., 2014, 12 (4), 282-92.
109. Zhang, R.-H.; Gao, J.-Y.; Guo, H.-T.; Scott, G. I.; Eason, A. R.; Wang, X.-M.; Ren, J. Inhibition of CYP2E1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction and apoptosis. Biochim. Biophys. Acta, 2013, 1832 (1), 128-141.
110. Watkins, P. B.; Kaplowitz, N.; Slattery, J. T.; Colonese, C. R.; Colucci, S. V.; Stewart, P. W.; Harris, S. C. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA, 2006, 296 (1), 87-93.
111. Lancaster, E. M.; Hiatt, J. R.; Zarrinpar, A. Acetaminophen hepatotoxicity: an updated review. Arch. Toxicol., 2014.
112. Nourjah, P.; Ahmad, S. R.; Karwoski, C.; Willy, M. Estimates of acetaminophen (Paracetomal)-associated overdoses in the United States. Pharmacoepidemiol. Drug Saf., 2006, 15 (6), 398-405.
113. Lesko, S. M.; Louik, C.; Vezina, R. M.; Mitchell, A. A. Asthma morbidity after the short-term use of ibuprofen in children. Pediatrics, 2002, 109 (2), E20.
114. Brandlistuen, R. E.; Ystrom, E.; Nulman, I.; Koren, G.; Nordeng, H. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. Int. J. Epidemiol., 2013, 42 (6), 1702-13.
115. Edelman, E. J.; Gordon, K. S.; Lo Re, V.; Skanderson, M.; Fiellin, D. A.; Justice, A. C.; Team, V. P. Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. Pharmacoepidemiol. Drug Saf., 2013, 22 (12), 1352-1356.
116. Hazai, E.; Vereczkey, L.; Monostory, K. Reduction of toxic metabolite formation of acetaminophen. Biochem. Biophys. Res. Commun., 2002, 291 (4), 1089-1094.
117. Jan, Y.-H.; Heck, D. E.; Dragomir, A.-C.; Gardner, C. R.; Laskin, D. L.; Laskin, J. D. Acetaminophen reactive intermediates target hepatic thioredoxin reductase. Chem. Res. Toxicol., 2014, 27 (5), 882-894.
118. Brune, K.; Renner, B.; Tiegs, G. Acetaminophen/paracetamol: A history of errors, failures and false decisions. Eur. J. Pain, 2014.
119. Moore, N. D.; Gulmez, E.; Blin, P. Is paracetamol hepatotoxic at normal doses? BMJ, 2013, 346.
120. Suzuki, A.; Yuen, N.; Walsh, J.; Papay, J.; Hunt, C. M.; Diehl, A. M. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin. Gastroenterol. Hepatol., 2009, 7 (8), 882-888.
121. Johnson, B. P.; Walisser, J. A.; Liu, Y.; Shen, A. L.; McDearmon, E. L.; Moran, S. M.; McIntosh, B. E.; Vollrath, A. L.; Schook, A. C.; Takahashi, J. S.; Bradfield, C. A. Hepatocyte circadian clock controls acetaminophen bioactivation through NADPH-cytochrome P450 oxidoreductase. Proc. Natl. Acad. Sci. U. S. A., 2014, 111 (52), 18757-18762.
122. Yang, C. S. Inhibition of carcinogenesis and toxicity by dietary constituents. Adv. Exp. Med. Biol., 2001, 500, 541-550.
123. Yang, C. S.; Chhabra, S. K.; Hong, J. Y.; Smith, T. J. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J. Nutr., 2001, 131 (3s), 1041S-5S.
124. Hu, J. J.; Yoo, J. S.; Lin, M.; Wang, E. J.; Yang, C. S. Protective effects of diallyl sulfide on acetaminophen-induced toxicities. Food Chem. Toxicol., 1996, 34 (10), 963-969.
125. Lin, M. C.; Wang, E. J.; Patten, C.; Lee, M. J.; Xiao, F.; Reuhl, K. R.; Yang, C. S. Protective effect of diallyl sulfone against acetaminophen- induced hepatotoxicity in mice. J. Biochem. Toxicol., 1996, 11 (1), 11-20.
126. Dai, Y.; Cederbaum, A. I. Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells. J. Pharmacol. Exp. Ther., 1995, 273 (3), 1497-1505.
127. Tanaka, E.; Terada, M.; Misawa, S. Cytochrome P450 2E1: its clinical and toxicological role. J. Clin. Phar. Ther., 2000, 25 (3), 165-175.
128. Spracklin, D. K.; Emery, M. E.; Thummel, K. E.; Kharasch, E. D. Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats. Acta Anaesthesiol. Scand., 2003, 47 (6), 765-70.
129. Sun, Q.; Wang, G.; Gao, L.; Shi, L.; Qi, Y.; Lv, X.; Jin, Y. Roles of CYP2e1 in 1,2-dichloroethane-induced liver damage in mice. Environ. Toxicol., 2015.
130. Wong, F. W.; Chan, W. Y.; Lee, S. S. Resistance to carbon tetrachloride- induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol. Appl. Pharmacol., 1998, 153 (1), 109-18.
131. Sohn, O. S.; Fiala, E. S.; Requeijo, S. P.; Weisburger, J. H.; Gonzalez, F. J. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Cancer Res., 2001, 61 (23), 8435-40.
132. Brady, J. F.; Li, D.; Ishizaki, H.; Yang, C. S. Effect of Diallyl Sulfide on Rat Liver Microsomal Nitrosamine Metabolism and Other Monooxygenase Activities. Cancer Res., 1988, 48 (21), 5937-5940.
133. Fanelli, S. L.; Castro, G. D.; de Toranzo, E. G.; Castro, J. A. Mechanisms of the preventive properties of some garlic components in the carbon tetrachloride-promoted oxidative stress. Diallyl sulfide; diallyl disulfide; allyl mercaptan and allyl methyl sulfide. Res. Commun. Mol. Pathol. Pharmacol., 1998, 102 (2), 163-174.
134. Brady, J. F.; Wang, M. H.; Hong, J. Y.; Xiao, F.; Li, Y.; Yoo, J. S.; Ning, S. M.; Lee, M. J.; Fukuto, J. M.; Gapac, J. M. Modulation of rat hepatic microsomal monooxygenase enzymes and cytotoxicity by diallyl sulfide. Toxicol. Appl. Pharmacol., 1991, 108 (2), 342-354.
135. Brady, J. F.; Ishizaki, H.; Fukuto, J. M.; Lin, M. C.; Fadel, A.; Gapac, J. M.; Yang, C. S. Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem. Res. Toxicol., 1991, 4 (6), 642-647.
136. Ha, H. R.; Chen, J.; Freiburghaus, A. U.; Follath, F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br. J. Clin. Pharmacol., 1995, 39 (3), 321-6.
137. Kim, Y. C.; Lee, A. K.; Lee, J. H.; Lee, I.; Lee, D. C.; Kim, S. H.; Kim, S. G.; Lee, M. G. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3- dimethyluric acid formation. Eur. J. Pharm. Sci., 2005, 26 (1), 114-23.
138. Pocernich, C. B.; Sultana, R.; Mohmmad-Abdul, H.; Nath, A.; Butterfield, D. A. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res. Brain Res. Rev., 2005, 50 (1), 14-26.
139. Price, T. O.; Ercal, N.; Nakaoke, R.; Banks, W. A. HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res., 2005, 1045 (1-2), 57-63.
140. Gil, L.; Martínez, G.; González, I.; Tarinas, A.; Alvarez, A.; Giuliani, A.; Molina, R.; Tápanes, R.; Pérez, J.; León, O. S. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol. Res., 2003, 47 (3), 217-224.
141. Steiner, J.; Haughey, N.; Li, W.; Venkatesan, A.; Anderson, C.; Reid, R.; Malpica, T.; Pocernich, C.; Butterfield, D. A.; Nath, A. Oxidative stress and therapeutic approaches in HIV dementia. Antioxid. Redox Signal., 2006, 8 (11-12), 2089-2100.
142. Li, W.; Li, G.; Steiner, J.; Nath, A. Role of Tat protein in HIV neuropathogenesis. Neurotox. Res., 2009, 16 (3), 205-220.
143. Buccigrossi, V.; Laudiero, G.; Nicastro, E.; Miele, E.; Esposito, F.; Guarino, A. The HIV-1 transactivator factor (Tat) induces enterocyte apoptosis through a redox-mediated mechanism. PLoS One, 2011, 6 (12).
144. Cota-Gomez, A.; Flores, A. C.; Ling, X.-F.; Varella-Garcia, M.; Flores, S. C. HIV-1 Tat increases oxidant burden in the lungs of transgenic mice. Free Radic. Biol. Med., 2011.
145. Aksenov, M. Y.; Hasselrot, U.; Bansal, A. K.; Wu, G.; Nath, A.; Anderson, C.; Mactutus, C. F.; Booze, R. M. Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci. Lett., 2001, 305 (1), 5-8.
146. Shah, A.; Kumar, S.; Simon, S. D.; Singh, D. P.; Kumar, A. HIV gp120- and methamphetamine-mediated oxidative stress induces astrocyte apoptosis via cytochrome P450 2E1. Cell Death Dis., 2013, 4, e850.
147. Louboutin, J.-P.; Agrawal, L.; Reyes, B. A. S.; Van Bockstaele, E. J.; Strayer, D. S. HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress. J. Neuropathol. Exp. Neurol., 2010, 69 (8), 801-816.
148. Ronaldson, P. T.; Bendayan, R. HIV-1 viral envelope glycoprotein gp120 produces oxidative stress and regulates the functional expression of multidrug resistance protein-1 (Mrp1) in glial cells. J. Neurochem., 2008, 106 (3), 1298-1313.
149. Deshmane, S. L.; Mukerjee, R.; Fan, S.; Del Valle, L.; Michiels, C.; Sweet, T.; Rom, I.; Khalili, K.; Rappaport, J.; Amini, S.; Sawaya, B. E. Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J. Biol. Chem., 2009, 284 (17), 11364-11373.
150. Isaguliants, M.; Smirnova, O.; Ivanov, A. V.; Kilpelainen, A.; Kuzmenko, Y.; Petkov, S.; Latanova, A.; Krotova, O.; Engström, G.; Karpov, V.; Kochetkov, S.; Wahren, B.; Starodubova, E. Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization. Hum. Vaccin. Immunother., 2013, 9 (10), 2111-2119.
151. Kumar, S.; Rao, P.; Earla, R.; Kumar, A. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin. Drug Metab. Toxicol., 2015, 11 (3), 343-55.
152. Sherman, K. E.; Thomas, D.; Chung, R. T. Human immunodeficiency virus and liver disease forum 2012. Hepatology, 2014, 59 (1), 307-17.
153. Krashin, D. L.; Merrill, J. O.; Trescot, A. M. Opioids in the management of HIV-related pain. Pain Physician, 2012, 15 (3 Suppl), ES157-68.
154. Kumar, S. Role of Cytochrome P450 Systems in Substance of Abuse Mediated HIV-1 Pathogenesis and NeuroAIDS. J. Drug Metab. Toxicol., 2012, 03 (01).
155. Fan, X.; Staitieh, B. S.; Jensen, J. S.; Mould, K. J.; Greenberg, J. A.; Joshi, P. C.; Koval, M.; Guidot, D. M. Activating the Nrf2- mediated antioxidant response element restores barrier function in the alveolar epithelium of HIV-1 transgenic rats. Am. J. Physiol. Lung Cell Mol. Physiol., 2013, 305 (3), L267-277.
156. Schafer, A.; Galuppo, P.; Fraccarollo, D.; Vogt, C.; Widder, J. D.; Pfrang, J.; Tas, P.; Barbosa-Sicard, E.; Ruetten, H.; Ertl, G.; Fleming, I.; Bauersachs, J. Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. Diabetes, 2010, 59 (8), 2001-9.
157. Swaminathan, K.; Kumar, S. M.; Clemens, D. L.; Dey, A. Inhibition of CYP2E1 leads to decreased advanced glycated end product formation in high glucose treated ADH and CYP2E1 overexpressing VL-17A cells. Biochim. Biophys. Acta, 2013, 1830 (10), 4407-16.
158. Woodcroft, K. J.; Hafner, M. S.; Novak, R. F. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology, 2002, 35 (2), 263-73.
159. Moncion, A.; Truong, N. T.; Garrone, A.; Beaune, P.; Barouki, R.; De Waziers, I. Identification of a 16-nucleotide sequence that mediates post-transcriptional regulation of rat CYP2E1 by insulin. J. Biol. Chem., 2002, 277 (48), 45904-10.
160. Kaut, O.; Schmitt, I.; Wullner, U. Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics, 2012, 13 (1), 87-91.
161. Shahabi, H. N.; Westberg, L.; Melke, J.; Hakansson, A.; Belin, A. C.; Sydow, O.; Olson, L.; Holmberg, B.; Nissbrandt, H. Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson's disease in a Swedish population. J. Neural. Transm., 2009, 116 (5), 567-73.
162. Yun, Y. P.; Casazza, J. P.; Sohn, D. H.; Veech, R. L.; Song, B. J. Pretranslational activation of cytochrome P450IIE during ketosis induced by a high fat diet. Mol. Pharmacol., 1992, 41 (3), 474-9.
163. Zong, H.; Armoni, M.; Harel, C.; Karnieli, E.; Pessin, J. E. Cytochrome P-450 CYP2E1 knockout mice are protected against highfat diet-induced obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab., 2012, 302 (5), E532-9.
164. Puccinelli, E.; Gervasi, P. G.; Pelosi, G.; Puntoni, M.; Longo, V. Modulation of cytochrome P450 enzymes in response to continuous or intermittent high-fat diet in pigs. Xenobiotica, 2013, 43 (8), 686-98.
165. Abdelmegeed, M. A.; Banerjee, A.; Yoo, S. H.; Jang, S.; Gonzalez, F. J.; Song, B. J. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J. Hepatol., 2012, 57 (4), 860-6.
166. Kumar, S.; Kumar, A. Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs. Alcohol Clin. Exp. Res., 2011, 35 (12), 2121-7.
167. Li, J.; Wei, D. Q.; Wang, J. F.; Yu, Z. T.; Chou, K. C. Molecular dynamics simulations of CYP2E1. Med. Chem., 2012, 8 (2), 208-21.
168. Johnson, E. F.; Connick, J. P.; Reed, J. R.; Backes, W. L.; Desai, M. C.; Xu, L.; Estrada, D. F.; Laurence, J. S.; Scott, E. E. Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges. Drug Metab. Dispos., 2014, 42 (1), 9-22.
169. Orr, S. T.; Ripp, S. L.; Ballard, T. E.; Henderson, J. L.; Scott, D. O.; Obach, R. S.; Sun, H.; Kalgutkar, A. S. Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J. Med. Chem., 2012, 55 (11), 4896-933.
170. Porubsky, P. R.; Battaile, K. P.; Scott, E. E. Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode. J. Biol. Chem., 2010, 285 (29), 22282-90.
171. Porubsky, P. R.; Meneely, K. M.; Scott, E. E. Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J. Biol. Chem., 2008, 283 (48), 33698-707.
172. Lewis, D. F.; Lake, B. G.; Bird, M. G.; Loizou, G. D.; Dickins, M.; Goldfarb, P. S. Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme-substrate and enzyme-inhibitor interactions. Toxicol. In vitro, 2003, 17 (1), 93-105.
173. Earla, R.; Kumar, S.; Wang, L.; Bosinger, S.; Li, J.; Shah, A.; Gangwani, M.; Nookala, A.; Liu, X.; Cao, L.; Jackson, A.; Silverstein, P. S.; Fox, H. S.; Li, W.; Kumar, A. Enhanced methamphetamine metabolism in rhesus macaque as compared with human: an analysis using a novel method of liquid chromatography with tandem mass spectrometry, kinetic study, and substrate docking. Drug Metab. Dispos., 2014, 42 (12), 2097-108.
174. Ruiz, M. E.; Gantner, M. E.; Talevi, A. Applications of nanosystems to anticancer drug therapy (Part II. Dendrimers, micelles, lipid-based nanosystems). Recent Pat. Anticancer Drug Discov., 2014, 9 (1), 99-128.
175. Golla, K.; Cherukuvada, B.; Ahmed, F.; Kondapi, A. K. Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS One, 2012, 7 (12), e51960.
176. Mahajan, S. D.; Aalinkeel, R.; Law, W. C.; Reynolds, J. L.; Nair, B. B.; Sykes, D. E.; Yong, K. T.; Roy, I.; Prasad, P. N.; Schwartz, S. A. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int. J. Nanomedicine, 2012, 7, 5301-14.
177. Gendelman, H. E.; Gelbard, H. A. Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Curr. Opin. HIV AIDS, 2014, 9 (6), 585-90.
178. Saiyed, Z. M.; Gandhi, N. H.; Nair, M. P. Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier. Int. J. Nanomedicine, 2010, 5, 157-66.
179. Mahajan, S. D.; Roy, I.; Xu, G.; Yong, K. T.; Ding, H.; Aalinkeel, R.; Reynolds, J.; Sykes, D.; Nair, B. B.; Lin, E. Y.; Prasad, P. N.; Schwartz, S. A. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr. HIV Res., 2010, 8 (5), 396-404.
180. Alam, M.; Zubair, S.; Farazuddin, M.; Ahmad, E.; Khan, A.; Zia, Q.; Malik, A.; Mohammad, O. Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis. Nanomedicine, 2013, 9 (2), 247-56.